MDT

89.9

+0.19%↑

VEEV

274.53

-3.46%↓

A

123.17

-1.34%↓

WBA

11.52

-0.6%↓

HQY

94.44

-3.76%↓

MDT

89.9

+0.19%↑

VEEV

274.53

-3.46%↓

A

123.17

-1.34%↓

WBA

11.52

-0.6%↓

HQY

94.44

-3.76%↓

MDT

89.9

+0.19%↑

VEEV

274.53

-3.46%↓

A

123.17

-1.34%↓

WBA

11.52

-0.6%↓

HQY

94.44

-3.76%↓

MDT

89.9

+0.19%↑

VEEV

274.53

-3.46%↓

A

123.17

-1.34%↓

WBA

11.52

-0.6%↓

HQY

94.44

-3.76%↓

MDT

89.9

+0.19%↑

VEEV

274.53

-3.46%↓

A

123.17

-1.34%↓

WBA

11.52

-0.6%↓

HQY

94.44

-3.76%↓

Search

Arcutis Biotherapeutics Inc

Avatud

SektorTervishoid

14.9 -1.26

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

14.69

Max

15.34

Põhinäitajad

By Trading Economics

Sissetulek

-14M

-25M

Müük

-5.5M

66M

Kasumimarginaal

-38.059

Töötajad

342

EBITDA

-14M

-19M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+43.32% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

13. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-169M

1.6B

Eelmine avamishind

16.16

Eelmine sulgemishind

14.9

Uudiste sentiment

By Acuity

50%

50%

168 / 376 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Arcutis Biotherapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. juuli 2025, 21:42 UTC

Omandamised, ülevõtmised, äriostud

Justice Department Won't Seek Injunction for T-Mobile Acquisition of U.S. Cellular

10. juuli 2025, 17:06 UTC

Omandamised, ülevõtmised, äriostud

Portugal Begins Process to Sell Stake in National Carrier -- Update

10. juuli 2025, 17:00 UTC

Suurimad hinnamuutused turgudel

K Wave Media Shares Drop After Convertible Note Agreement With Anson Funds

10. juuli 2025, 16:31 UTC

Omandamised, ülevõtmised, äriostud

Blackstone Makes $664 Million Counteroffer for Warehouse REIT Amid Bidding War -- 2nd Update

10. juuli 2025, 23:47 UTC

Market Talk

Gold Edges Higher Amid Lingering Global Trade Tensions -- Market Talk

10. juuli 2025, 23:40 UTC

Market Talk

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

10. juuli 2025, 22:36 UTC

Market Talk

Tourism Holdings' Profit Warning Less Concerning Than Others -- Market Talk

10. juuli 2025, 22:23 UTC

Market Talk

New Law Creates Winners and Losers Among Renewable-Energy Projects -- Market Talk

10. juuli 2025, 20:50 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

10. juuli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10. juuli 2025, 20:00 UTC

Omandamised, ülevõtmised, äriostud

Toyota Tsusho America Completes Acquisition of Radius Recycling

10. juuli 2025, 19:56 UTC

Market Talk

Gold Rises on Inflation Concerns -- Market Talk

10. juuli 2025, 19:33 UTC

Market Talk

Oil Snaps Winning Streak As Oversupply Concerns Return -- Market Talk

10. juuli 2025, 19:21 UTC

Market Talk

U.S. Natural Gas Rebound on Benign Storage Build -- Market Talk

10. juuli 2025, 18:46 UTC

Market Talk

Mexican Industrial Production Seen as Mixed in May -- Market Talk

10. juuli 2025, 18:15 UTC

Market Talk

Brazil's Bullish Outlook Expected to Survive Trump Tariffs -- Market Talk

10. juuli 2025, 18:03 UTC

Market Talk
Tulu

Travel Agency Investors Cautiously Optimistic After Delta Report -- Market Talk

10. juuli 2025, 17:57 UTC

Market Talk

US Labor Shortage Could Weigh on Business, Economic Growth -- Market Talk

10. juuli 2025, 17:34 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Conagra Falls While Simply Good Foods Adapts. What's Eating Food Companies. -- Barrons.com

10. juuli 2025, 17:34 UTC

Market Talk

Canada Vows Fight Over Trump's Copper Tariffs -- Market Talk

10. juuli 2025, 17:20 UTC

Market Talk

Copper Climbs as Futures Wrangle With Trump Tariff -- Market Talk

10. juuli 2025, 17:20 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

10. juuli 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

10. juuli 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

10. juuli 2025, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

10. juuli 2025, 16:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10. juuli 2025, 16:02 UTC

Market Talk

Global Equities Roundup: Market Talk

10. juuli 2025, 16:02 UTC

Market Talk

Embraer Expected to Bear Brunt of U.S. Tariffs on Brazil -- Market Talk

10. juuli 2025, 16:01 UTC

Omandamised, ülevõtmised, äriostud

Investor AB: Advanced Instruments' Acquisition of Nova Biomedical Completed

10. juuli 2025, 15:41 UTC

Market Talk

U.S. Natural Gas Storage Surplus Holds Steady -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Arcutis Biotherapeutics Inc Prognoos

Hinnasiht

By TipRanks

43.32% tõus

12 kuu keskmine prognoos

Keskmine 20.38 USD  43.32%

Kõrge 29 USD

Madal 14 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Arcutis Biotherapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

7

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

12.42 / 14.93Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

168 / 376 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.